Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 1/20 | 0.80 |
| ▸ | MLNR | O43193 | 1/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | DRD2 | P14416 | 1/20 | 0.80 |
| ▸ | PKM | P14618 | 1/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.80 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.80 |
| ▸ | HTR2A | P28223 | 1/20 | 0.80 |
| ▸ | HTR2C | P28335 | 1/20 | 0.80 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11205596 | 0.99 | P2RX7 (0.82) | P2RX7LMNAMEN1MLNRNR1I2 | |
| SCHEMBL1152747 | 0.99 | P2RX7 (0.84) | P2RX7LMNAMEN1MLNRNR1I2 | |
| SCHEMBL15346498 | 0.99 | P2RX7 (0.84) | P2RX7LMNAMEN1MLNRNR1I2 | |
| Hydrochloric Acid SCHEMBL11374610 | 0.98 | P2RX7 (0.80) | P2RX7LMNAMEN1MLNRNR1I2 | |
| SCHEMBL1153384 | 0.98 | P2RX7 (0.88) | P2RX7LMNAMEN1MLNRNR1I2 | |
| Hydrochloric Acid SCHEMBL11205601 | 0.98 | P2RX7 (0.82) | P2RX7LMNAMEN1MLNRNR1I2 | |
| SCHEMBL1152607 | 0.98 | P2RX7 (0.83) | P2RX7LMNAMEN1MLNRNR1I2 | |
| Hydrochloric Acid SCHEMBL11195570 | 0.97 | P2RX7 (0.80) | P2RX7LMNAMEN1MLNRNR1I2 | |
| SCHEMBL1153001 | 0.96 | P2RX7 (0.88) | P2RX7LMNAMEN1MLNRNR1I2 | |
| SCHEMBL1152790 | 0.93 | P2RX7 (0.83) | P2RX7LMNAMEN1MLNRNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4250176-A | BENZIMIDAZOLE-2-ONE, BENZOTHIAZOL-2-ONE, OR BENZOXAZOL-2-ONE SUBSTITUTIONS, ANTIANAPHALACTIC AGENTS, ANTIHISTAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-02-10 | — | — | US | claimed |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2013-10-31 | — | — | US | disclosed |
| US-8475804-B2 | Compositions and methods for treatment of filovirus-mediated diseases | U.S. ARMY MEDICAL RESEARCH AND MATERIAL COMMAND (US) | 2013-07-02 | — | — | US | disclosed |
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | ZALICUS INC. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028564-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | P2RX7 912/4885LMNA 156/4885MEN1 3612/4885 |
| US-20130289024-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF FILOVIRUS-MEDIATED DISEASES | FLNA, FLNB, PIGS | P2RX7 912/4885LMNA 156/4885MEN1 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.